CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 280.51 AUD 0.86%
Market Cap: 135.8B AUD
Have any thoughts about
CSL Ltd?
Write Note

CSL Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CSL Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
CSL Ltd
ASX:CSL
Other Long-Term Assets
$929m
CAGR 3-Years
20%
CAGR 5-Years
20%
CAGR 10-Years
12%
Immutep Ltd
ASX:IMM
Other Long-Term Assets
AU$1.3m
CAGR 3-Years
42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Other Long-Term Assets
$2.1m
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Other Long-Term Assets
AU$1.2m
CAGR 3-Years
-27%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Other Long-Term Assets
AU$20.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CSL Ltd
Glance View

Market Cap
135.6B AUD
Industry
Biotechnology
Economic Moat
None

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSL Intrinsic Value
235.9 AUD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is CSL Ltd's Other Long-Term Assets?
Other Long-Term Assets
929m USD

Based on the financial report for Jun 30, 2024, CSL Ltd's Other Long-Term Assets amounts to 929m USD.

What is CSL Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
12%

Over the last year, the Other Long-Term Assets growth was 2%. The average annual Other Long-Term Assets growth rates for CSL Ltd have been 20% over the past three years , 20% over the past five years , and 12% over the past ten years .

Back to Top